Jefferson Capital, Inc. (JCAP)

Oncternal Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023
Cash & Equivalents	26.99	35.51	14.37
Cash & Short-Term Investments	26.99	35.51	14.37
Cash Growth	-	147.07%	-
Receivables	1,578	1,515	1,005
Prepaid Expenses	41.01	28.75	22.51
Restricted Cash	3.42	2.74	6.23
Total Current Assets	1,649	1,582	1,048
Property, Plant & Equipment	-	4.45	4.03
Goodwill	57.69	57.68	57.17
Other Intangible Assets	8.95	10.24	6.52
Total Assets	1,716	1,654	1,115
Accounts Payable	69.03	72.17	36.48
Current Portion of Leases	-	1.22	-
Total Current Liabilities	69.03	73.38	36.48
Long-Term Debt	1,212	1,195	770.93
Long-Term Leases	-	3.65	4.38
Total Liabilities	1,281	1,272	811.78
Common Stock	-	-	28.8
Retained Earnings	446.35	398.12	276.43
Comprehensive Income & Other	-11.71	-15.59	-1.64
Shareholders' Equity	434.64	382.53	303.59
Total Liabilities & Equity	1,716	1,654	1,115
Total Debt	1,212	1,200	775.3
Net Cash (Debt)	-1,185	-1,164	-760.93
Working Capital	1,580	1,509	1,011
Tangible Book Value	368	314.61	239.9

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q